Executive Summary
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Canadian Solar Inc. et al.vsMaxeon Solar Pte. Ltd.
Canadian Solar successfully instituted its IPR against Maxeon Solar regarding solar cell fabrication technology. The Board found a reasonable likelihood of obviousness for several claims over various combinations of prior art, authorizing trial on multiple claims.
Anker Innovations Ltd.vsPowermat Technologies Ltd.
Anker Innovations Ltd. successfully convinced the PTAB to institute IPR proceedings against Powermat Technologies Ltd.'s patent (8626461). The Board found a reasonable likelihood of prevailing on anticipation and obviousness grounds regarding inductive power coupling technology.
Zhejiang Lingdi Digital Technology Co., Ltd.vsCLO Virtual Fashion, Inc.
The PTAB denied the institution of an IPR challenging CLO Virtual Fashion's digital clothing patent (10,733,773) after finding that the petitioner failed to demonstrate a reasonable likelihood of success. The Board rejected the obviousness arguments based on impermissible hindsight and unsupported expert testimony.
Askeladden L.L.C.vs--
The PTAB granted institution of IPR for U.S. Patent 7,480,637 against Jabaa L.L.C., finding Askeladden L.L.C. showed a reasonable likelihood of prevailing on claims related to biometric authentication.
LEDUP MANUFACTURING GROUP LTD.vsSeasonal Specialties, LLC
The Petitioner successfully demonstrated unpatentability for the majority of claims (1, 2, 4–7, 9–15) based on anticipation and obviousness over various combinations of prior art. However, the Board rejected arguments regarding Claims 3 and 8, finding insufficient articulation in the Petition to support those findings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.